Celosia Therapeutics
A privately held pre-clinical stage gene therapy company, developing solutions for neurodegenerative diseases that have limited alternative therapeutic options.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | AUD16.8m | Series A | |
| Total Funding | 000k | ||
Related Content
Celosia Therapeutics is a pioneering biotech company focused on developing groundbreaking gene therapies to treat neurodegenerative diseases that currently lack effective therapeutic options. The company operates in the biotechnology and pharmaceutical market, primarily serving patients suffering from conditions such as ALS, MND, LGD disease, frontotemporal dementia, and Dravet Syndrome. Celosia Therapeutics leverages advances in gene therapy and a deeper understanding of molecular pathways to modify the neuronal microenvironment, aiming to significantly improve patient outcomes.
The business model of Celosia Therapeutics involves extensive research and development (R&D) to create innovative treatments, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, partnerships with pharmaceutical companies, and potential licensing agreements.
Celosia Therapeutics' team comprises scientists, clinicians, innovators, and entrepreneurs dedicated to redefining the treatment landscape for individuals with devastating neurodegenerative diseases. The company's mission is to change lives forever by providing new hope and effective solutions for patients and their families.
Keywords: gene therapies, neurodegenerative diseases, ALS, MND, LGD disease, frontotemporal dementia, Dravet Syndrome, biotech, pharmaceutical, R&D, clinical trials.